TY - JOUR
T1 - Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis
AU - Pepple, Kathryn L.
AU - Lin, Phoebe
N1 - Funding Information:
Financial Disclosure(s): The author(s) made the following disclosures: K.P.: Support Research to Prevent Blindness Career Development Award (New York, NY), The Alcon Research Institute Young Investigators Grant (Fort Worth, TX), and the National Institute of Health, NEI K08EY023998.
Funding Information:
P.L.: Supported National Eye Institute Grant K08 EY022948, a Collins Medical Trust Grant, Research to Prevent Blindness Career Development Award. The manuscript is supported by Core Grants P30 EY010572 and P30 EY01730 from the National Institute of Health (Bethesda, MD) and by unrestricted departmental funding from Research to Prevent Blindness (New York, NY).
Publisher Copyright:
© 2018 American Academy of Ophthalmology
PY - 2018/12
Y1 - 2018/12
N2 - The interleukin (IL)-23/IL-17 axis plays a central role in the pathogenesis of immune-mediated diseases such as psoriasis, psoriatic arthritis, Crohn's disease, and uveitis. Therefore, targeting the IL-23/IL-17 axis has become the focus of multiple clinical trials for drug development in patients with autoimmune diseases. We briefly describe the biology of the IL-23/IL-17 axis and its relevance to the pathogenesis of experimental and clinical uveitis, and review the monoclonal antibody therapies targeting this pathway. Finally, 2 ongoing phase 2 trials of the anti–IL-23 biologic therapy ustekinumab (STELARA, Janssen Biotech Inc, Horsham, PA) in patients with noninfectious uveitis are introduced.
AB - The interleukin (IL)-23/IL-17 axis plays a central role in the pathogenesis of immune-mediated diseases such as psoriasis, psoriatic arthritis, Crohn's disease, and uveitis. Therefore, targeting the IL-23/IL-17 axis has become the focus of multiple clinical trials for drug development in patients with autoimmune diseases. We briefly describe the biology of the IL-23/IL-17 axis and its relevance to the pathogenesis of experimental and clinical uveitis, and review the monoclonal antibody therapies targeting this pathway. Finally, 2 ongoing phase 2 trials of the anti–IL-23 biologic therapy ustekinumab (STELARA, Janssen Biotech Inc, Horsham, PA) in patients with noninfectious uveitis are introduced.
UR - http://www.scopus.com/inward/record.url?scp=85049355381&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049355381&partnerID=8YFLogxK
U2 - 10.1016/j.ophtha.2018.05.014
DO - 10.1016/j.ophtha.2018.05.014
M3 - Review article
C2 - 30458922
AN - SCOPUS:85049355381
SN - 0161-6420
VL - 125
SP - 1977
EP - 1983
JO - Ophthalmology
JF - Ophthalmology
IS - 12
ER -